Format

Send to

Choose Destination
  • Showing results for high expression of soluble cd155 in estrogen receptor negative breast cancer. Your search for High expression of soluble CD155 in estrogen receptor-negative breast cance retrieved no results.
Breast Cancer. 2019 Aug 1. doi: 10.1007/s12282-019-00999-8. [Epub ahead of print]

High expression of soluble CD155 in estrogen receptor-negative breast cancer.

Author information

1
Department of Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, 305-8575, Japan.
2
Department of Immunology, Faculty of Medicine, University of Tsukuba, Tsukuba, 305-8575, Japan.
3
Department of Breast and Endocrine Surgery, University of Tsukuba Hospital, Tsukuba, 305-8576, Japan.
4
Life Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance (TARA), University of Tsukuba, Tsukuba, 305-8575, Japan.
5
Department of Immunology, Faculty of Medicine, University of Tsukuba, Tsukuba, 305-8575, Japan. kazukos@md.tsukuba.ac.jp.

Abstract

BACKGROUND:

The poliovirus receptor (CD155) is expressed ubiquitously at low levels on both hematopoietic and nonhematopoietic cells, but its expression is upregulated in various tumor cells. An activating receptor DNAM-1 expressed on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells binds to CD155 and mediates the cytotoxic activity of CTLs and NK cells against tumors. Unlike mouse tissues, human tissues express a soluble form of CD155 (sCD155), which is a splicing isoform of CD155 lacking the transmembrane region. We previously reported that the serum levels of sCD155 were higher in lung, gastrointestinal, breast, and gynecologic cancer patients than in healthy donors. Here, we focus on breast cancer patients.

METHODS:

To analyze the association between serum level of sCD155 and clinicopathological parameters of breast cancer, we quantified sCD155 in the sera of 153 breast cancer patients by sandwich ELISA.

RESULTS:

sCD155 levels in the sera of breast cancer patients were positively correlated with patient age, disease stage, and invasive tumor size. Moreover, they were higher in patients with estrogen receptor (ER)-negative cancers than in those with ER-positive tumors, and higher in those with Ki-67-high cancers than in those with Ki-67-low cancers.

CONCLUSIONS:

The serum level of sCD155 is correlated with high risk factors in breast cancer.

KEYWORDS:

DNAM-1; ER-negative; Ki-67-high; Soluble CD155

PMID:
31372841
DOI:
10.1007/s12282-019-00999-8

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center